Inovio Pharmaceuticals (INO) Inovio (INO) appreciated roughly 16% on Thursday as concern about the novel coronavirus intensified. Recently, the Coalition for Epidemic Preparedness Innovations (CEPI)grantedInovio $9 million in funding to begin a clinical trial for a vaccine to prevent infection from the Wuhan coronavirus (2019-nCoV). ARK believes CEPI's grant highlights the strength of Inovio's platform in developing novel immunotherapies for both infectious disease and cancer. from Catherine Wood's ARK investment newsletter